| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer
2 companies
Bruce Car is Chief Scientific Officer at AGIO, with reported holdings spanning 2 companies. Bruce Car's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $643K at current prices.
Bruce Car's largest disclosed position is in AGIO as Chief Scientific Officer, worth about $523K.
Bruce Car has 15 Form 4 filings on record from January 2020 to February 2026, across 2 companies: Chief Scientific Officer at Biohaven (BHVN), 2022–2026; Chief Scientific Officer at Agios Pharmaceuticals (AGIO), 2020–2022.
The 27 reported transactions were 12 option or other derivative awards, 7 option exercises, 7 tax withholdings and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $1.0M and no sales.
The only open-market purchase was 30,000 shares of BHVN at an average $33.58 on June 17, 2024, about $1.0M. Twelve months later BHVN was down 56%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2024 | BHVN Biohaven Ltd. | Chief Scientific Officer | Buy | 30,000 | $33.58 | $1,007,490.00 | New | +18.3% | -55.9% |